AFT agrees distribution for Crystaderm in China

09 July 2024 AFT agrees distribution for Crystaderm in China AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today announces an agreement with Hainan Haiyao Co. Ltd (Shenzhen Stock Exchange SZ:000566) to distribute Crystaderm® cream in China, the second largest pharma market in the world1. Crystaderm cream is a proprietary product that treats skin infections by the slow release of hydrogen peroxide onto the skin as an alternative to topical antibiotics, which if misused risk development of drug resistant bacteria2. AFT Pharmaceuticals Managing Director Dr Hartley Atkinson said: “We are excited to announce our partnership with Haiyao, an established pharmaceutical distribution company in China. “We anticipate the launch will occur during this calendar year and believe that that there is a significant potential for this product in such a large population base.” Hayao Pharmaceuticals Chairman Mr. Wang Jianping stated: “We are delighted to partner with AFT to bring Crystaderm to Chinese consumers. There has been an unmet clinical demand in the Chinese acne market for a long time. As a new acne drug and anti-infective product without hormones and antibiotics, Crystaderm has been proven to be effective. Haiyao will carry out the commercialization process of Crystaderm in China. We are excited about its potential and developing our relationship with AFT.” For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial Officer. For more information: Investors Media Dr Hartley Atkinson Richard Inder Managing Director The Project AFT Pharmaceuticals Tel: +64 21 645 643 Tel: +64 9488 0232 Footnotes 1.https://www.statista.com/statistics/245473/market-share-of-the-leading-10-global-pharmaceutical-markets/ 2. Williamson DA et al (2015) NZMJ, 128 (1426) : 103-9 About AFT Pharmaceuticals AFT is a growing New Zealand based multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs . Our business model is to develop and in-license products for in our markets of Australia, New Zealand, Singapore, Malaysia, Hong Kong, USA, Canada, EU ex Ireland and UK, and to out-license our products to local licensees and distributors to over 125 countries around the world. For more information about the company, visit our website www.aftpharm.com. About Hainan Haiyao Hainan Haiyao Co., Ltd., a well-established Chinese pharmaceutical company, was founded in 1965. It is the first batch of listed pharmaceutical manufacturing enterprises in China and the first listed company in the pharmaceutical industry in Hainan Province. The company's main products cover intermediates, APIs, chemical innovative drugs, modern traditional Chinese medicine, biopharmaceuticals, cellular immunity, high-end medical devices, and other fields. A number of core drugs such as high value-added generic drugs and characteristic drugs have high popularity in the industry. There are multiple best-selling varieties nationwide and they are exported to dozens of countries and regions.